Physician profile
Adi Smolinsky
NPI 1831352889
$1,864.25
in general payments reported to CMS, 2019-2025
20 companies · $559 in 2025
The $559 reported for 2025 was more than what 83% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $841 · 2020: $26.86 · 2021: $54.88 · 2023: $270 · 2024: $113 · 2025: $559.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $684 · Education: $258.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $683.69 |
| Education | $258.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celularity INC. | $600.00 | 2019 | |
| Astellas Pharma US INC | $355.83 | 2023-2025 | Veozah, Myrbetriq |
| Millicent US INC | $189.94 | 2023-2025 | Femring, Intrarosa, Femlyv |
| Mayne Pharma Commercial LLC | $160.10 | 2023-2025 | |
| Abbvie INC. | $136.36 | 2019-2023 | Lo Loestrin Fe |
| Medtronic USA, INC. | $117.49 | 2019 | |
| Pfizer INC. | $48.77 | 2023 | |
| Sumitomo Pharma America, INC. | $35.27 | 2025 | Myfembree |
| Therapeuticsmd, INC. | $31.37 | 2019 | |
| Amag Pharmaceuticals, INC. | $27.78 | 2019-2020 | |
| Organon LLC | $27.06 | 2024-2025 | Nexplanon |
| Exeltis, USA INC. | $19.39 | 2025 | Slynd |
| Lilly USA, LLC | $17.23 | 2025 | Zepbound |
| Evofem Biosciences, INC. | $15.33 | 2025 | Phexxi, Solosec, Phexx |
| Theratechnologies INC. | $14.99 | 2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acella Pharmaceuticals, LLC | $14.98 | 2024 | NP Thyroid 60 |
| Avion Pharmaceuticals | $13.95 | 2020 | |
| Novo Nordisk INC | $13.52 | 2025 | Wegovy |
| Dysis Medical, INC. | $13.16 | 2021 | |
| Medicem INC. | $11.73 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adi Smolinsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.